PPARA and Sepsis: We found that administration of pemafibrate, a novel selective PPARα modulator (SPPARMα) with improved selectivity, potency, and safety profile (Ishibashi et al, 2016), improved PPARα function and reduced the metabolic dysregulation during sepsis.